Breastfeeding reduces the risk of infectious diseases in children by up to 50 %. Human Milk Oligosaccharides (HMOs) play a major role in this process. Jennewein Biotechnologie recently initiated the first clinical trial with a mixture of HMOs emulating the profile found in human milk with a mix of the five most abandoned HMOs including 2 ´- FL, 3- FL, LNt, 3`- SL and 6`- SL.
Now, non-breastfed babies also have the opportunity to profit from the beneficial effects of HMOs. The biotech company offers to subscribers the opportunity to get a 2´-FL and LNnt HMO - Mix sample for free.
Fill in the form to get your free sample!